Literature DB >> 8348152

The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm.

E Reyniers1, L Vits, K De Boulle, B Van Roy, D Van Velzen, E de Graaff, A J Verkerk, H Z Jorens, J K Darby, B Oostra.   

Abstract

Fragile X syndrome is characterized at the molecular level by amplification of a (CGG)n repeat and hypermethylation of a CpG island preceeding the open reading frame of the fragile X gene (FMR-1) located in Xq27.3. Anticipation in this syndrome is associated with progressive amplification of the (CGG)n repeat from a premutation to a full mutation through consecutive generations. Remarkably, expansion of the premutation to the full mutation is strictly maternal. To clarify this parental influence we studied FMR-1 in sperm of four male fragile X patients. This showed that only the premutation was present in their sperm, although they had a full mutation in peripheral lymphocytes. This might suggest that expansion of the premutation to the full mutation in FMR-1 does not occur in meiosis but in a postzygotic stage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348152     DOI: 10.1038/ng0693-143

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  79 in total

1.  FMR1 CGG-repeat instability in single sperm and lymphocytes of fragile-X premutation males.

Authors:  S L Nolin; G E Houck; A D Gargano; H Blumstein; C S Dobkin; W T Brown
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 2.  Comparative genomics and molecular dynamics of DNA repeats in eukaryotes.

Authors:  Guy-Franck Richard; Alix Kerrest; Bernard Dujon
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

3.  Longitudinal interviews of couples diagnosed with diminished ovarian reserve undergoing fragile X premutation testing.

Authors:  Lisa M Pastore; Logan B Karns; Karen Ventura; Myra L Clark; Richard H Steeves; Nancy Callanan
Journal:  J Genet Couns       Date:  2013-06-14       Impact factor: 2.537

4.  Cloned human FMR1 trinucleotide repeats exhibit a length- and orientation-dependent instability suggestive of in vivo lagging strand secondary structure.

Authors:  M C Hirst; P J White
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

5.  RS46(DXS548) genotyping of reproductive cells: approaching preimplantation testing of the fragile-X syndrome.

Authors:  J C Dreesen; J P Geraedts; J C Dumoulin; J L Evers; M H Pieters
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

6.  FMR1 fully expanded mutation with minimal methylation in a high functioning fragile X male.

Authors:  Z Wang; A K Taylor; J A Bridge
Journal:  J Med Genet       Date:  1996-05       Impact factor: 6.318

7.  The DNA replication program is altered at the FMR1 locus in fragile X embryonic stem cells.

Authors:  Jeannine Gerhardt; Mark J Tomishima; Nikica Zaninovic; Dilek Colak; Zi Yan; Qiansheng Zhan; Zev Rosenwaks; Samie R Jaffrey; Carl L Schildkraut
Journal:  Mol Cell       Date:  2013-11-27       Impact factor: 17.970

Review 8.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

9.  A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response.

Authors:  Roman Alpatov; Bluma J Lesch; Mika Nakamoto-Kinoshita; Andres Blanco; Shuzhen Chen; Alexandra Stützer; Karim J Armache; Matthew D Simon; Chao Xu; Muzaffar Ali; Jernej Murn; Sladjana Prisic; Tatiana G Kutateladze; Christopher R Vakoc; Jinrong Min; Robert E Kingston; Wolfgang Fischle; Stephen T Warren; David C Page; Yang Shi
Journal:  Cell       Date:  2014-05-08       Impact factor: 41.582

10.  A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases.

Authors:  F Rousseau; D Heitz; J Tarleton; J MacPherson; H Malmgren; N Dahl; A Barnicoat; C Mathew; E Mornet; I Tejada
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.